80 related articles for article (PubMed ID: 3592710)
21. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
22. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
Papatheofanis FJ
J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
[TBL] [Abstract][Full Text] [Related]
23. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
24. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
[TBL] [Abstract][Full Text] [Related]
25. [Low-dose cisplatin and UFT for hormone refractory prostate cancer].
Hoshi S; Ohyama C; Namiki S; Hagisawa S; Satoh M; Saito S; Ono K; Shirasaka T; Arai Y
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1773-8. PubMed ID: 12402428
[TBL] [Abstract][Full Text] [Related]
26. [Combined treatment for pain from bone metastases in patients with prostate cancer].
Ren X; Ying J; Yao D; Ye C; Jiang Y
Zhonghua Nan Ke Xue; 2004 Mar; 10(3):188-90. PubMed ID: 15080063
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate.
Andros EA; Danesghari F; Crawford ED
Clin Invest Med; 1993 Dec; 16(6):510-5. PubMed ID: 7516835
[TBL] [Abstract][Full Text] [Related]
28. [Update of experience with prostatic cancer].
Nitecki S; Kuten A; Cohen Y
Harefuah; 1993 Mar; 124(5):261-5, 320, 319. PubMed ID: 8495915
[TBL] [Abstract][Full Text] [Related]
29. [Prostatic cancer: pathological analysis of autopsied cases].
Takahashi Y; Mayuzumi T; Satoh J
Hinyokika Kiyo; 1986 Jun; 32(6):835-9. PubMed ID: 3766343
[TBL] [Abstract][Full Text] [Related]
30. [Combination therapy with estrogen and UFT in newly diagnosed prostatic cancer (poorly differentiated, stage D2)].
Kondo I; Miura T; Fujii H; Harada M; Fukushima S; Kubota Y; Hosaka M
Hinyokika Kiyo; 1996 Mar; 42(3):201-6. PubMed ID: 8619389
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer metastasis to supraclavicular lymph node.
Hobdy EM; Shafi NQ; Kummar S
Clin Adv Hematol Oncol; 2004 Apr; 2(4):223-4; discussion 224. PubMed ID: 16163185
[No Abstract] [Full Text] [Related]
32. Bone pain palliation with 85Sr therapy.
Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
[TBL] [Abstract][Full Text] [Related]
33. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma.
Fixemer T; Remberger K; Bonkhoff H
Prostate; 2003 Feb; 54(2):79-87. PubMed ID: 12497580
[TBL] [Abstract][Full Text] [Related]
35. [Bilateral testicular metastasis of an adenocarcinoma of the prostate].
Giannakopoulos X; Bai M; Grammeniatis E; Stefanou D; Agnanti N
Ann Urol (Paris); 1994; 28(5):274-6. PubMed ID: 7825987
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
37. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
38. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
39. Radiotherapy combined with hormone therapy for prostate cancer.
Tsuya A; Kawai T; Fukushima S; Shida K; Shimazaki J
Strahlentherapie; 1974 Jul; 148(1):24-34. PubMed ID: 4216125
[TBL] [Abstract][Full Text] [Related]
40. Effect of estrogen therapy on metastatic carcinoma of the prostate.
Anikwe RM
Int Surg; 1977 Oct; 62(10):532-6. PubMed ID: 591215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
